SCHEMBL13246993

SCHEMBL13246993

FC(F)(F)c1cc(C(c2ccncc2)c2cnc[nH]2)c2cccnc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 8/20 0.43
HRH4 Q9H3N8 4/20 0.43
CYP3A4 P08684 3/20 0.43
CYP2D6 P10635 3/20 0.43
HRH1 P35367 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
ADRA2A P08913 5/20 0.34
CYP19A1 P11511 1/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
PARP1 P09874 1/20 0.33
ADRA2B P18089 4/20 0.33
ADRA2C P18825 4/20 0.33
ADRA1A P35348 4/20 0.33
ADRA1D P25100 3/20 0.33
ADRA1B P35368 3/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13267921 0.83 HRH3 (0.34) HRH3HRH4CYP3A4CYP2D6HRH1
SCHEMBL13247041 0.80 ADRA2A (0.46) HRH3HRH4CYP3A4CYP2D6HRH1
SCHEMBL10000116 0.76 ADRA2A (0.40) HRH3HRH4CYP3A4CYP2D6CYP1A2
SCHEMBL10000109 0.74 ADRA2A (0.35) HRH3HRH4CYP3A4CYP2D6CYP1A2
SCHEMBL700313 0.73 ADRA2A (0.49) HRH3HRH4CYP3A4CYP2D6CYP1A2
SCHEMBL10316451 0.72 ADRA2A (0.34) HRH3HRH4CYP3A4CYP2D6CYP1A2
SCHEMBL10000120 0.71 ADRA2A (0.34) HRH3HRH4CYP3A4CYP2D6CYP1A2
SCHEMBL10000100 0.70 ADRA2A (0.43) CYP3A4CYP2D6CYP1A2CYP2C19ADRA2A
SCHEMBL10000113 0.70 HRH3 (0.41) HRH3HRH4CYP3A4CYP2D6HRH1
SCHEMBL3068612 0.70 HRH3 (0.43) HRH3HRH4CYP3A4CYP2D6HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162450-B1 ((BICYLICHETEROARYL) IMIDAZOLYL) METHYLHETEROARYL COMPOUNDS AS ADRENERGIC RECEPTOR AGONISTS ALLERGAN INC (US) 2015-02-25 EP disclosed
US-8383646-B2 Therapeutic ((bicylicheteroaryl)imidazolyl) methylheteroaryl compounds ALLERGAN, INC. (US) 2013-02-26 US disclosed
US-8383646-B2 Therapeutic ((bicylicheteroaryl)imidazolyl) methylheteroaryl compounds ALLERGAN, INC. (US) 2013-02-26 US disclosed
US-20100190823-A1 Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds ALLEGERGAN INC. (US) 2010-07-29 US disclosed
WO-2008147786-A1 ((BICYLICHETEROARYL) IMIDAZOLYL) METHYLHETEROARYL COMPOUNDS AS ADRENERGIC RECEPTOR AGONISTS ALLERGAN, INC. (US) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190823-A1 Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds OAT, HMGCR, GOT2 HRH3 472/4885HRH4 238/4885CYP3A4 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.